CALIFORNIA PHARMACY-LICENSE RESTRICTION BILL AMENDMENT
Executive Summary
CALIFORNIA PHARMACY-LICENSE RESTRICTION BILL AMENDMENT to allow mfrs. involved in delivery of home health care services to obtain pharmacy licenses is under discussion among state legislative staffers and the state's pharmacists assn., and four mfrs. Representatives from Baxter Travenol, Abbott, American Hospital Supply, and J&J met on May 2 with the Caifornia Pharmacists Assn. and staff from State Sen. Art Torres' office to discuss a proposed amendment to the bill. The revised language was reportedly drafted by Baxter, AHSC and Abbott. The bill, introduced by Torres and passed April 28 by the state's Senate Business & Professions Cmte., would deny pharmacy licenses to "a mfr. of pharmaceuticals or to a corporation or partnership in which 10% or more of the shares or business is owned by a mfr. of pharmaceuticals." The bill is indicative of concern in the pharmacy community about the growing interest among mfrs. in direct delivery of health services. The mfrs.' suggested amendment to the bill would allow a mfr. to hold a pharmacy license if "the mfr. generally provides drugs to a patient in the patient's home or at a health care institution and if the mfr. generally does not dispense such drugs to a patient within its pharmacy." Reportedly, Senate floor action on the bill is being delayed while discussions on the revision continue.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth